The wonders of anticoagulation.
作者信息
Ten Cate Hugo
机构信息
Thrombosis Expertise Center, Maastricht University Medical Centre, Maastricht, Netherlands.
CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.
出版信息
Front Cardiovasc Med. 2025 Jan 13;11:1517109. doi: 10.3389/fcvm.2024.1517109. eCollection 2024.
Abstract
摘要
相似文献
1
The wonders of anticoagulation.抗凝治疗的神奇之处。
Front Cardiovasc Med. 2025 Jan 13;11:1517109. doi: 10.3389/fcvm.2024.1517109. eCollection 2024.
2
Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants.患者对口服抗凝药物治疗的依从性：维生素 K 拮抗剂与直接口服抗凝剂的比较。
Int J Cardiol. 2021 Jun 15;333:162-166. doi: 10.1016/j.ijcard.2021.03.003. Epub 2021 Mar 8.
3
A new strategy for anticoagulation: The factor XI inhibitors.一种新的抗凝策略：因子 XI 抑制剂。
Eur J Intern Med. 2023 Oct;116:8-15. doi: 10.1016/j.ejim.2023.08.001. Epub 2023 Aug 4.
4
Self-reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants.从维生素K拮抗剂转换为直接口服抗凝剂的患者自我报告的治疗依从性及不依从的预测因素。
Res Pract Thromb Haemost. 2020 Mar 14;4(4):586-593. doi: 10.1002/rth2.12316. eCollection 2020 May.
5
Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.荷兰心房颤动口服抗凝治疗的持续性：一项监测研究。
Res Pract Thromb Haemost. 2019 Oct 24;4(1):141-153. doi: 10.1002/rth2.12261. eCollection 2020 Jan.
6
Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.优化心房颤动患者非维生素K拮抗剂口服抗凝治疗的依从性和持续性
Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A42-A55. doi: 10.1093/eurheartj/suab152. eCollection 2022 Feb.
7
Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants.心房颤动患者口服抗凝治疗的依从性。聚焦于非维生素K拮抗剂口服抗凝药。
Thromb Haemost. 2017 Jan 26;117(2):209-218. doi: 10.1160/TH16-10-0757. Epub 2016 Nov 10.
8
Discontinuation of anticoagulant treatment: from clinical trials to medication persistence.抗凝治疗的中断：从临床试验到药物持续性
Curr Med Res Opin. 2015;31(10):1841-4. doi: 10.1185/03007995.2015.1086991. Epub 2015 Sep 14.
9
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.真实世界中，为降低房颤患者卒中风险，患者对口服抗凝药物的持续应用及依从性。
Europace. 2016 Aug;18(8):1150-7. doi: 10.1093/europace/euv421. Epub 2016 Jan 31.
10
Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.与老年患者口服抗凝药物种类选择相关的因素：一项观察性研究。
J Cardiovasc Pharmacol Ther. 2020 Jul;25(4):332-337. doi: 10.1177/1074248420917811. Epub 2020 Apr 8.
本文引用的文献
1
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid.直接口服抗凝剂：何时使用及何时避免使用的快速入门指南
Thromb Haemost. 2025 Jul;125(7):611-617. doi: 10.1055/a-2451-4014. Epub 2024 Nov 18.
2
Asundexian versus Apixaban in Patients with Atrial Fibrillation.阿孙地昔与阿哌沙班用于心房颤动患者的比较
N Engl J Med. 2025 Jan 2;392(1):23-32. doi: 10.1056/NEJMoa2407105. Epub 2024 Sep 1.
3
Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin-K antagonists: A retrospective German claims data analysis.与维生素K拮抗剂相比，阿哌沙班、依度沙班和利伐沙班（而非达比加群）与更高的死亡率相关：一项德国索赔数据分析回顾。
J Intern Med. 2024 Oct;296(4):362-376. doi: 10.1111/joim.20006. Epub 2024 Sep 2.
4
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.Milvexian 与阿哌沙班在房颤卒中预防中的比较：LIBREXIA 房颤试验的原理和设计。
Am Heart J. 2024 Nov;277:145-158. doi: 10.1016/j.ahj.2024.08.011. Epub 2024 Aug 29.
5
Factor XI inhibitors - Rising stars in anti-thrombotic therapy?因子 XI 抑制剂 - 抗血栓治疗的后起之秀？
J Neurol Sci. 2024 Sep 15;464:123157. doi: 10.1016/j.jns.2024.123157. Epub 2024 Jul 29.
6
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?XI 因子抑制剂会取代当前的抗凝剂用于房颤卒中预防吗？
Curr Cardiol Rep. 2024 Sep;26(9):911-917. doi: 10.1007/s11886-024-02100-y. Epub 2024 Jul 23.
7
Factor XI inhibition in patients with acute coronary syndrome.急性冠状动脉综合征患者的因子XI抑制
Eur Heart J Suppl. 2024 Apr 17;26(Suppl 1):i29-i34. doi: 10.1093/eurheartjsupp/suae013. eCollection 2024 Apr.
8
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study.心房颤动中与高基线直接口服抗凝剂水平相关的早期出血更多：MAS研究
Blood Adv. 2024 Sep 24;8(18):4913-4923. doi: 10.1182/bloodadvances.2024013126.
9
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.依达赛珠单抗治疗因子 Xa 抑制剂相关急性脑出血。
N Engl J Med. 2024 May 16;390(19):1745-1755. doi: 10.1056/NEJMoa2313040.
10
The DOAC-FRAIL study, evaluation of direct oral anticoagulant-levels in acutely admitted frail older patients: An exploratory study.DOAC-FRAIL研究：急性收治的体弱老年患者直接口服抗凝剂水平评估——一项探索性研究
J Am Geriatr Soc. 2024 Jul;72(7):2249-2253. doi: 10.1111/jgs.18894. Epub 2024 Mar 29.
Zotero 插件